AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05937438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
Study NCT06499896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTP-101-C
Description: MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
Study NCT06036849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
Study NCT06036849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
Study NCT06396949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia study form
Description: Fibromyalgia study form, consisting of clinical measurement, Fibromyalgia impact questionnaire (FIQ), Beck Anxiety Questionnaire and Beck Depression Questionnaire, Short-Form (SF)-36, who applied to the outpatient clinic with fibromyalgia will be filled in detail.
Study NCT06396949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
Study NCT06396949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic Diaphragm Thickness Measurement
Description: Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity) (millimeter-mm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
Study NCT05495737 — intervention group
Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC Training
Description: Two-Day MCP-PC Training for Nurses (including mock patient/simulation with actor) with a Pre- and Post-Training Assessment
Study NCT06447623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a kind of TKI inhibitor.
Study NCT05495737 — intervention group
Intervention type: BEHAVIORAL
Intervention: Meaning-Centered Psychotherapy/MCP-PC
Description: 3 sessions, completed over the course of 3-6 weeks in the participant's home
Study NCT05495737 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treatment As Usual/TAU
Description: Research team will provide:~1. feedback about level of distress at time of screening~2. local referral for psychological care
Study NCT06500130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Surface Gastric Mapping
Description: All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
Study NCT06447623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 Inhibitor
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Study NCT06447623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor
Description: Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
Study NCT06447623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and Fulvestrant
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study NCT06447623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase inhibitor and Fulvestrant
Description: Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
Study NCT05425732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: 0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
Study NCT05425732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: 0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
Study NCT04516538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination
Description: test for evaluating a person's cognitive functions and memory capacity
Study NCT04516538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6 Minutes Walk Test
Description: a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
Study NCT06591026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Description: One digital helpline session that includes a structured cognitive coping skills brief intervention.
Study NCT04516538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed up and go
Description: A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
Study NCT06284213 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: This is an observational study with no interventions.
Study NCT05258071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirepemat
Description: Oral use
Study NCT05258071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use
Study NCT06185205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: High Dose Rate treatment delivery
Study NCT06532162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine Paracervical Block
Description: A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Study NCT06532162 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Paracervical Injection
Description: A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Digital Diet Diary
Description: Participants will be asked to complete the Fitbit 3-day food record, which consists of inputting each food and beverage consumed for two weekdays and 1 weekend day into the Fitbit application. This digital diary includes taking photos of each food and beverage consumed during the 3 day food record period on the participant's iphone or ipad.
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: NHANES Food Frequency Questionnaire (FFQ)
Description: Participants will complete the the Food Frequency questionnaire which indicates usual food intake over the past year.
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fitbit data collection
Description: Participants will be asked to wear a Fitbit continuously (24/7) for one week to track steps and activity intensity. The Fitbit is worn on the wrist and uses accelerometer and heart rate technology to quantify steps taken and integrated barometric altimeter to measure activity intensity. The resulting Fitbit data will be automatically pulled from the participant's smartphone or study device.
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life questionnaire
Description: The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) includes questions about participant's quality of life during the past week, self-reported general health, self reported chronic conditions and psychological distress using a scale from 1-5, 1=excellent, 5= poor. A lower total score indicates better qualify of life.
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire
Description: The Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Godin Exercise Leisure-Time questionnaire
Description: The Godin Exercise Leisure-Time questionnaire measures the frequency of strenuous, moderate, and mild exercise for periods of 15 minutes or more during the participant's free time throughout a typical week. The scoring using the formula leisure score index (LSI) which is obtained using the following formula: (frequency of mild × 3) + (frequency of moderate × 5) + (frequency of strenuous × 9).
Study NCT05434702 — intervention group
Intervention type: BEHAVIORAL
Intervention: Zoom interviews
Description: A subset of 30 participants (10 African American, 10 Hispanic, 10 non-Hispanic white) will participate in semi-structured interviews to explore (a) sociocultural, environmental, and individual factors associated with lifestyle behaviors; (b) awareness of American Cancer Society (ACS) guidelines, current practices, and essential intervention modules (ex. integrating cultural foods and preferences) to provide study team with information needed to develop healthy behavior interventions for young adult cancer survivors.
Study NCT06212999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study NCT05292846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulation
Description: Apixaban Dabigatran Edoxaban Rivaroxaban
Study NCT05545696 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AI on algorithm
Description: The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
Study NCT05545696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AI off algorithm
Description: The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Arm 2, intraperitoneal (IP) Mitomycin C monotherapy: dosing divided into two 60-mL syringes, 30 mg per syringe. 30 mg will be given at time = 0, and the remaining 10 mg of the dose will be given at time = 60 minutes. Part of Arm 4: Mitomycin C co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Part of Arms 3 and 4, intraperitoneal (IP)cisplatin co-therapy: 75 mg/m2 for 60 minutes, mixed in 1 L of 0.9% sodium chloride. For cisplatin-based HIPEC, intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
Study NCT04847063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heated Intraperitonial Chemotherapy
Description: Heated Intraperitonial Chemotherapy (HIPEC) with with standardized doses of chemotherapeutic agents as indicated by the subject's Arm assignment
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm 1, intraperitoneal (IP) Oxaliplatin: 200 mg/m2 for 90 minutes, mixed in 250 mL of 5% dextrose solution. For oxaliplatin-based HIPEC, intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Part of Arm 1, for oxaliplatin-based HIPEC: intravenous 5-fluorouracil given at a dose of 400 mg/m2 in 250 mL 0.9% sodium chloride over 10 minutes, co-administered with intravenous leucovorin at 20 mg/m2 in a separate bag of 250 mL 0.9% sodium chloride
Study NCT04847063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Part of Arms 3 and 4, for cisplatin-based HIPEC: intravenous sodium thiosulfate given as a loading dose of 7.5 g/m2 in 150 mL 0.9% sodium chloride at the time of introducing cisplatin into the perfusion circuit, followed by a 12-hour pump-based infusion of 25.56 g/m2 in 1 L 0.9% sodium chloride
Study NCT05728450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light amplification by stimulated emission of radiation (LASER)
Description: * The points for application of laser acupuncture will be cleaned before application. All patients in the study group will be submitted to infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will inserted into the main current supply and on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for definite location of acupuncture points
Study NCT04967833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Biological: Tumor Infiltrating Lymphocytes (TIL) Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT06580067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pray Until Something Happens (PUSH)
Description: Self-monitoring of outcomes + alerts/reminders + use of PUSH
Study NCT06580067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pray Until Something Happens (PUSH)
Description: Self-monitoring of outcomes + alerts/reminders + use of PUSH
Study NCT05718128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocardiomyocardial biopsy
Description: Endocardiomyocardial biopsy
Study NCT05240456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta3-Agonists, Adrenergic
Description: The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
Study NCT05240456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic drug, Solifenacin
Description: Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
Study NCT06580067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring of outcomes + alerts/reminder
Study NCT04516538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)
Description: The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest).
Study NCT05237050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound therapy associated with relaxation
Description: Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~Sessions will start with relaxation. Then, sound therapy will be delivered using weighted medical tuning forks which resonate at a specific frequency. At the end of the session, the patient will be invited to take a short rest.
Study NCT05237050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation alone
Description: Each patient will attend a total of 3 sessions of about 15 minutes each, once by week.~The procedure will be exactly the same than the other arm (relaxation, rest time), but the operator will not activate any tuning fork (so there will be no sound delivered during the session).
Study NCT05318222 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole genome sequencing (WGS)
Description: WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
Study NCT06101706 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fatigue assessment
Description: FACIT-F questionnaire and Visual Analog Scale for fatigue
Study NCT06101706 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life assessment
Description: PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
Study NCT06101706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assess severity of psoriatic arthritis
Description: DAPSA score
Study NCT06101706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assess severity of cutaneous psoriasis
Description: PASI score
Study NCT06488183 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
Description: preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
Study NCT05095701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Live Attenuated Varicella Vaccine
Description: The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
Study NCT05095701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Freeze Dired Dilution)
Description: The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
Study NCT04805736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: Image-guided microwave ablation 7-10 days prior to surgery